Does Rallies show Form 4 insider transactions for ADMA?

Yes. Rallies tracks ADMA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ADMA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ADMA. It does not provide personalized investment advice.

ADMA (ADMA Biologics, Inc.) Stock Analysis - Insider Trades

ADMA Biologics, Inc. (ADMA) is a publicly traded Healthcare sector company. As of May 21, 2026, ADMA trades at $8.65 with a market cap of $1.94B and a P/E ratio of 12.47. ADMA moved -0.87% today. Year to date, ADMA is -52.52%; over the trailing twelve months it is -58.12%. Its 52-week range spans $7.21 to $25.67. Analyst consensus is buy with an average price target of $23.67. Rallies surfaces ADMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ADMA stock inside the company?

Recent ADMA insider activity includes Grossman Jerrold B bought 12.50K, Grossman Jerrold B bought 12.50K, Grossman Adam S sold 15.00K, Grossman Adam S sold 6.00K, and Kestenberg-Messina Kaitlin M. sold 10.10K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ADMA Key Metrics

Key financial metrics for ADMA
Metric	Value
Price	$8.65
Market Cap	$1.94B
P/E Ratio	12.47
EPS	$0.69
Dividend Yield	0.00%
52-Week High	$25.67
52-Week Low	$7.21
Volume	3.88M
Avg Volume	0
Revenue (TTM)	$509.86M
Net Income	$165.35M
Gross Margin	61.27%

Recent ADMA Insider Trades

Grossman Jerrold B bought 12.50K (~$100.13K) on May 12, 2026.
Grossman Jerrold B bought 12.50K (~$100.13K) on May 11, 2026.
Grossman Adam S sold 15.00K (~$227.40K) on Mar 16, 2026.
Grossman Adam S sold 6.00K (~$90.96K) on Mar 16, 2026.
Kestenberg-Messina Kaitlin M. sold 10.10K (~$157.80K) on Mar 9, 2026.

Latest ADMA News

ADMA Biologics Flat Q1 Revenue, ASCENIV Sales Jump 28% While BIVIGAM Plunges 54% — May 6, 2026
ADMA Biologics Shares Fall 16% After DSO Hits 113 Days — Mar 30, 2026
ADMA Biologics Refutes Short-Seller Report Over Disclosed Short Position — Mar 25, 2026
ADMA Biologics director buys 7,000 shares at $15.39, posts 28.8% net margin — Mar 9, 2026
Adma Biologics Upgraded to Zacks #1 Strong Buy Following 6.1% Estimate Rise — Mar 3, 2026

ADMA Analyst Consensus

3 analysts cover ADMA: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $23.67.

Common questions about ADMA

Who is trading ADMA stock inside the company?: Recent ADMA insider activity includes Grossman Jerrold B bought 12.50K, Grossman Jerrold B bought 12.50K, Grossman Adam S sold 15.00K, Grossman Adam S sold 6.00K, and Kestenberg-Messina Kaitlin M. sold 10.10K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ADMA?: Yes. Rallies tracks ADMA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ADMA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ADMA. It does not provide personalized investment advice.